Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection DOI Open Access
Vlad Ionescu, Camelia Cristina Diaconu, Gina Gheorghe

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(8), С. 3733 - 3733

Опубликована: Апрель 15, 2025

The gut microbiome, a complex community of microorganisms residing in the intestinal tract, plays dual role colorectal cancer (CRC) development, acting both as contributing risk factor and protective element. This review explores mechanisms by which microbiota contribute to CRC, emphasizing inflammation, oxidative stress, immune evasion, production genotoxins microbial metabolites. Fusobacterium nucleatum, Escherichia coli (pks+), Bacteroides fragilis promote tumorigenesis inducing chronic generating reactive oxygen species, producing virulence factors that damage host DNA. These can also evade antitumor response suppressing cytotoxic T cell activity increasing regulatory populations. Additionally, microbial-derived metabolites such secondary bile acids trimethylamine-N-oxide (TMAO) have been linked carcinogenic processes. Conversely, microbiota, including Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii, homeostasis short-chain fatty (SCFAs) like butyrate, exhibit anti-inflammatory anti-carcinogenic properties. beneficial microbes enhance barrier integrity, modulate responses, inhibit tumor proliferation. Understanding dynamic interplay between pathogenic is essential for developing microbiome-based interventions, probiotics, prebiotics, fecal transplantation, prevent or treat CRC. Future research should focus on identifying biomarkers early CRC detection exploring personalized microbiome-targeted therapies. A deeper understanding host–microbiota interactions may lead innovative strategies management improved patient outcomes.

Язык: Английский

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomedicines, Год журнала: 2025, Номер 13(2), С. 422 - 422

Опубликована: Фев. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Язык: Английский

Процитировано

1
The probiotic enhances donor microbiota stability and improves the efficacy of fecal microbiota transplantation for treating colitis DOI Creative Commons

Jingjing Fan,

Ying Wu, Xing Wang

и другие.

Journal of Advanced Research, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

1
Cross-talks between osteoporosis and gut microbiome DOI
Shiva Shankar Jha, Naveen Jeyaraman,

Madhan Jeyaraman

и другие.

World Journal of Orthopedics, Год журнала: 2025, Номер 16(3)

Опубликована: Март 12, 2025

Язык: Английский

Процитировано

0
Impact of Microbiota Diversity on Inflammatory Bowel Disease DOI Creative Commons
Ashwag Jaman Al-zahrani,

Basma M. Al-Hebshi,

Zolfekar A. Yahia

и другие.

Microorganisms, Год журнала: 2025, Номер 13(4), С. 710 - 710

Опубликована: Март 21, 2025

Inflammatory bowel disease (IBD) is a chronic condition that includes two main types, Crohn’s (CD) and ulcerative colitis (UC), involving inflammation of the gastrointestinal (GI) tract. The exact cause IBD unknown but could be combination genetic, environmental, immune system factors. This study investigated impact on microbiota diversity by evaluating differences in microbial composition control group (A) healthy individuals (B) patients. Sixty biopsies were collected from participants recruited hospitals Makkah, Saudi Arabia. Biopsy specimens taken during colonoscopy examination, bacterial identification was performed extracting ribosomal DNA sigmoid colon using DNeasy Blood & Tissue Kit. Metagenomics bioinformatics analyses then conducted to analyze compare groups. results showed varieties core microbiome species 3.81% greater patients than members group. Furthermore, between groups significantly variations within each Differences detected relative abundance Clostridium nexile, Ruminococcus gnavus, faecis, Escherichia coli. These indicate play role pathogenesis suggest can serve as biomarker for diagnosing monitoring its progression.

Язык: Английский

Процитировано

0
Role of Antioxidants in Modulating the Microbiota–Gut–Brain Axis and Their Impact on Neurodegenerative Diseases DOI Open Access
Natalia Kurhaluk, Piotr Kamiński, Rafał Bilski

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(8), С. 3658 - 3658

Опубликована: Апрель 12, 2025

This narrative review presents the role of antioxidants in regulating gut microbiota and impact on gut–brain axis, with a particular focus neurodegenerative diseases, such as Alzheimer’s (AD) Parkinson’s disease (PD). These diseases are characterised by cognitive decline, motor dysfunction, neuroinflammation, all which significantly exacerbated oxidative stress. elucidates contribution damage to progression explores potential mitigate these pathological processes through modulation associated pathways. Based recent studies retrieved from reputable databases, including PubMed, Web Science, Scopus, this article outlines mechanisms influence health exert neuroprotective effects. Specifically, it discusses how antioxidants, polyphenols, vitamins, flavonoids, contribute reduction reactive oxygen species (ROS) production thereby promoting neuronal survival minimising brain. In addition, modulating key molecular pathways involved stress NF-κB, Nrf2, MAPK, PI3K/AKT pathways, regulate ROS generation, inflammatory cytokine expression, antioxidant responses essential for maintaining cellular homeostasis both central nervous system. complex relationship between gut-derived metabolites, stress, highlighting dysbiosis—an imbalance microbiota—can exacerbate accelerating AD PD. The also examines short-chain fatty acids (SCFAs) produced beneficial bacteria attenuate neuroinflammation damage. Furthermore, therapeutic microbiota-targeted interventions, delivery probiotics prebiotics, innovative strategies restore microbial support brain health. By synthesising current knowledge interplay underlying neurodegeneration, highlights promise antioxidant-based interventions mitigating progression. It need further research into antioxidant-rich dietary microbiota-focused therapies promising avenues prevention treatment diseases.

Язык: Английский

Процитировано

0
Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection DOI Open Access
Vlad Ionescu, Camelia Cristina Diaconu, Gina Gheorghe

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(8), С. 3733 - 3733

Опубликована: Апрель 15, 2025

The gut microbiome, a complex community of microorganisms residing in the intestinal tract, plays dual role colorectal cancer (CRC) development, acting both as contributing risk factor and protective element. This review explores mechanisms by which microbiota contribute to CRC, emphasizing inflammation, oxidative stress, immune evasion, production genotoxins microbial metabolites. Fusobacterium nucleatum, Escherichia coli (pks+), Bacteroides fragilis promote tumorigenesis inducing chronic generating reactive oxygen species, producing virulence factors that damage host DNA. These can also evade antitumor response suppressing cytotoxic T cell activity increasing regulatory populations. Additionally, microbial-derived metabolites such secondary bile acids trimethylamine-N-oxide (TMAO) have been linked carcinogenic processes. Conversely, microbiota, including Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii, homeostasis short-chain fatty (SCFAs) like butyrate, exhibit anti-inflammatory anti-carcinogenic properties. beneficial microbes enhance barrier integrity, modulate responses, inhibit tumor proliferation. Understanding dynamic interplay between pathogenic is essential for developing microbiome-based interventions, probiotics, prebiotics, fecal transplantation, prevent or treat CRC. Future research should focus on identifying biomarkers early CRC detection exploring personalized microbiome-targeted therapies. A deeper understanding host–microbiota interactions may lead innovative strategies management improved patient outcomes.

Язык: Английский

Процитировано

0